Hyperfine (NASDAQ:HYPR – Get Free Report) and Beta Bionics (NASDAQ:BBNX – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, institutional ownership, risk and earnings.
Analyst Ratings
This is a breakdown of recent ratings and price targets for Hyperfine and Beta Bionics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Hyperfine | 1 | 1 | 3 | 0 | 2.40 |
| Beta Bionics | 1 | 4 | 7 | 0 | 2.50 |
Hyperfine currently has a consensus target price of $2.03, indicating a potential upside of 162.37%. Beta Bionics has a consensus target price of $21.90, indicating a potential upside of 1.01%. Given Hyperfine’s higher probable upside, equities analysts plainly believe Hyperfine is more favorable than Beta Bionics.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Hyperfine | $11.40 million | 7.21 | -$35.57 million | ($0.38) | -2.04 |
| Beta Bionics | $100.25 million | 9.73 | -$73.20 million | ($1.65) | -13.14 |
Hyperfine has higher earnings, but lower revenue than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Hyperfine has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500. Comparatively, Beta Bionics has a beta of 3.37, meaning that its share price is 237% more volatile than the S&P 500.
Profitability
This table compares Hyperfine and Beta Bionics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Hyperfine | -210.75% | -97.88% | -61.81% |
| Beta Bionics | -61.31% | -26.30% | -23.25% |
Insider and Institutional Ownership
15.0% of Hyperfine shares are held by institutional investors. 26.3% of Hyperfine shares are held by company insiders. Comparatively, 5.3% of Beta Bionics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Beta Bionics beats Hyperfine on 8 of the 14 factors compared between the two stocks.
About Hyperfine
Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products in the United States. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors. Hyperfine, Inc. was founded in 2014 and is based in Guilford, Connecticut.
About Beta Bionics
Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.
Receive News & Ratings for Hyperfine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hyperfine and related companies with MarketBeat.com's FREE daily email newsletter.
